Prognostic factors for patients with advanced non‐small cell lung cancer treated with gemcitabine‐platinum as first‐line therapy in an observational setting in C hina

Background This study examined the prognostic factors associated with survival in advanced non‐small cell lung cancer ( NSCLC ) patients receiving gemcitabine‐platinum regimens as first‐line therapy in real‐world clinical settings in C hina. Methods Data was analyzed from a multinational, prospective, non‐interventional, observational study of individuals receiving gemcitabine‐platinum regimens as first‐line therapy for NSCLC , focusing on 300 patients from mainland C hina. A C ox regression model was used to determine the association of 38 prognostic factors, including patient smoking characteristics, with overall survival. Results In these 300 patients, the mean age was 58.9 (±10.8) years, with males comprising 71% of the population. Thirty percent of patients had an Eastern Cooperative Oncology Group performance status ( PS ) of 0 and 70% had a PS of 1. The majority of patients had NSCLC of adenocarcinoma origin (57%). Multivariate C ox regression analyses adjusted for baseline factors revealed that gender, tumor ( T) staging, metastasis ( M) staging, liver metastases, serum albumin, and superior vena cava obstruction were significant prognostic factors. Smoking during therapy was not significantly associated with survival, although numbers were small for this variable ( n = 16). Weight loss of >10% was a significant prognostic factor for adverse events. Conclusions Gender, T staging, M staging, liver metastases, superior vena cava obstruction, and serum albumin are prognostic factors affecting overall survival in mainland C hinese patients receiving first‐line gemcitabine‐platinum regimens for advanced NSCLC . These negative prognostic factors may warrant further investigation in clinical trials.